Cynvenio Biosystems is a commercial-stage clinical diagnostics company that develops the LiquidBiopsy multi-template technology for molecular characterization of tumor cells from a standard blood draw. The platform delivers ultra-high sample purity and recovery enabling downstream molecular analysis by next-generation sequencing and PCR, and supports simultaneous analysis of ctcDNA, ctDNA, and germline DNA from a single blood sample. Cynvenio’s product suite includes automated instrumentation, consumables and reagents, patient sample kits, and bioinformatics. Its ClearID blood test is available from the company’s CLIA lab or clinical partners and is reimbursable in the United States. The company plans to use proceeds from the financing to advance clinical development and commercialization programs and to establish commercial and customer support infrastructure. Cynvenio is headquartered in Westlake Village, California (Los Angeles) and is establishing a China-based joint venture backed by an additional $10 million, bringing committed capital for this phase to $35.5 million.

Total raised

$26M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2015